California Stem Cell Institute Picks Industry Veteran as President

Click to view the privacy policy. Required fields are indicated by an asterisk (*) Email Country * Afghanistan Aland Islands Albania Algeria Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, the Democratic Republic of the Cook Islands Costa Rica Cote d’Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican City State) Honduras Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People’s Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People’s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, the former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Martinique Mauritania Mauritius Mayotte Mexico Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Norway Oman Pakistan Palestine Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Reunion Romania Russian Federation Rwanda Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Martin (French part) Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch part) Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania, United Republic of Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Vietnam Virgin Islands, British Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Sign up for our daily newsletter Get more great content like this delivered right to you! Country After a 6-month search, the California Institute for Regenerative Medicine (CIRM) has announced a new president. Predictably, the $3 billion agency is turning to a veteran of the private sector to guide it through a phase where industry savvy will be critical to its survival.Randy Mills, who spent the last 10 years as CEO of the stem cell-focused Osiris Therapeutics, will take the helm as the agency plans for an uncertain financial future and attempts to move more of its research to the clinic. “We now reach a time in our CIRM life which is sort of mid-life,” the governing board’s chair, Jonathan Thomas, said at a meeting today in Burlingame, California. Since the 2004 California ballot initiative that funded the new agency with bond sales, CIRM has awarded about $1.7 billion in grants to scientists at 65 institutions, including university medical schools and private companies. But with funding from those bonds set to run out in 2017, CIRM is working to sweeten its relationship with industry and fulfill its mandate of getting therapies to patients.Mills fits right into that goal, Jeff Sheehy, a CIRM board member and HIV patient advocate, tells ScienceInsider. “We’re getting someone who’s actually taken a stem cell product to market.” Under Mills’s leadership, Columbia, Maryland-based Osiris became the first company to receive regulatory approval for a stem cell drug. Canadian regulators in 2012 approved Prochymal to treat complications from bone marrow transplants. “We need something like that to happen with some of our projects,” Sheehy says. The board’s choice “reflects an evolution of CIRM and how they look at themselves,” says Michael May, CEO of the Centre for Commercialization and Regenerative Medicine in Toronto, Canada, who in 2012 served on an Institute of Medicine panel tasked with reviewing CIRM’s structure and policies. “The message is [one of] being more business-like.” Mills is viewed as a pioneer in the stem cell industry, May adds, and may help cultivate partnerships that support CIRM as it looks for new potential funding sources.Mills, who holds a Ph.D. in drug development, has served for 5 years on CIRM’s grant review board. He replaces Alan Trounson, a leading in vitro fertilization researcher who headed the agency for 6 years before announcing last October that he would step down to be closer to his family in Australia.

Leave a Reply

Your email address will not be published. Required fields are marked *